Year: 2024
Type: article
Abstract: Glioblastoma (GBM) remains one of the most lethal brain cancers. CAR T cells targeting IL13Rα2 have shown tumour shrinkage and extended survival in some patients, but challenges remain, such as sustaining T-cell activity and overcoming the tumour microenvironment (TME). Here we show a new “armoured” CAR T (NS007) to better tackle the immunosuppressive TME and enhance persistence in solid tumours.
Source: Immuno-Oncology Technology
Authors: M. Mangolini, S. Srivastava, E. Souster, Y. Yang, R. Karatill, L. Schultz, B. Ma, D. Pombal, A. Ramon, M. Greenig, P. Sormanni, S. Cordoba, S. Onuoha
Institution: University of Cambridge
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,170
OpenAlex ID: W4405374488